S87521 |
Pirarubicin (Hydrochloride) |
MedMol | 96% |
- 提示:详情请下载说明书。
- 产品描述: Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors
- 靶点: Topoisomerase II
- 体外研究: Pirarubicin 是一种拓扑异构酶 II 抑制剂。 Pirarubicin 对 M5076 和 Ehrlich 细胞具有抑制活性,IC50 分别为 0.366 和 0.078 μM。Pirarubicin 对 M5076 细胞的细胞毒性低于对 Ehrlich 细胞的细胞毒性,这是由于 M5076 细胞中拓扑异构酶 II 的表达远低于 Ehrlich 细胞。 Pirarubicin (2.5,5,10 μg/mL) 在膀胱癌 (T24、EJ、5637、J82 和 UM-UC-3) 细胞中以剂量依赖性方式显著诱导自噬。此外,Pirarubicin (5 μg/mL) 通过抑制膀胱癌细胞中的 mTOR/p70S6K/4E-BP1 诱导细胞凋亡,这种作用因抑制自噬而增强
- 体内研究: 在急性心脏毒性大鼠中,与对照组相比,Pirarubicin (18 mg/kg,iv) 显著提高 BNP、CK-MB、CTnT、LDH 和 MDA 的血清水平。在急性心脏毒性模型中,Pirarubicin Hydrochloride 还可以降低心率,降低 R 波电压,延长 QT 间期
- 参考文献:
1. Takigawa N, et al. Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines. Gan To Kagaku Ryoho. 1993 May;20(7):929-35. 2. Nagai K, et al. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol. 2002 Mar;49(3):244-50. Epub 2002 Jan 8. 3. Li K, et al. Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells. Biochem Biophys Res Commun. 2015 May 1;460(2):380-5. 4. Wang YD, et al. Cardioprotective effects of rutin in rats exposed to pirarubicin toxicity. J Asian Nat Prod Res. 2017 Oct 27:1-13.
- 溶解性: Soluble in DMSO
- 保存条件: -20℃
- 配置溶液浓度参考:
1mg 5mg 10mg 1 mM 1.506 ml 7.529 ml 15.058 ml 5 mM 0.301 ml 1.506 ml 3.012 ml 10 mM 0.151 ml 0.753 ml 1.506 ml 50 mM 0.03 ml 0.151 ml 0.301 ml
- 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)